Efficacy of Brigatinib After Progression on Alectinib or Ceritinib: Does One Drug Work in a Pretreated Heterogeneous ALK-Positive NSCLC Population?

J Thorac Oncol. 2023 Mar;18(3):e28-e29. doi: 10.1016/j.jtho.2022.11.028.

Authors

Edyta Maria Urbanska¹, Jens Benn Sørensen², Eric Santoni-Rugiu³

Affiliations

¹ Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Electronic address: Edyta.Maria.Urbanska@regionh.dk.
² Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
³ Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

PMID: 36842817
DOI: 10.1016/j.jtho.2022.11.028

No abstract available

Publication types

Letter
Comment

MeSH terms

Carbazoles / pharmacology
Carbazoles / therapeutic use
Carcinoma, Non-Small-Cell Lung* / drug therapy
Humans
Lung Neoplasms* / drug therapy
Protein Kinase Inhibitors / therapeutic use
Receptor Protein-Tyrosine Kinases

Substances

ceritinib
alectinib
brigatinib
Carbazoles
Receptor Protein-Tyrosine Kinases
Protein Kinase Inhibitors